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Bile acids are synthesized from cholesterol and are known to
solubilize cholesterol in the gallbladder and promote the digestion
and absorption of dietary fats and fat-soluble vitamins (A, D, E
and K) in the intestines. The production of bile acids is also known
to be one of the predominant mechanisms for excretion of excess
cholesterol from the body1. In addition to their beneﬁcial effects,
bile acids also produce toxic effects in the liver. It is becoming
increasingly evident that bile acids exert various biological effects
by activating different signaling pathways. However, the concept
of bile acids acting as signaling molecules is recent. It was not
until the past two decades that studies have reported that bile acids
act as natural ligands for the farnesoid X receptor (FXRα)2–4.
Following this discovery, bile acids have been shown to activate
other nuclear receptors (pregnane X receptor, vitamin D receptor),
G protein coupled receptors (GPCRs) (G-protein-coupled bile acid
receptor 5 (TGR5), muscarinic receptor 2 (M2), sphingosine-
1-phosphate receptor 2 (S1PR2)) and cellular signaling pathways
(c-Jun N-terminal kinase (JNK1/2), protein kinase B (AKT), and
extracellular regulated protein kinases (ERK1/2))5,6. Bile acids
have also been implicated in the inﬂammatory response and
various liver diseases, as well as the promotion of cancers such
as colon cancer and cholangiocarcinoma6–8. The emerging role of
bile acids as hormones and nutrient signaling molecules helped
contribute to our understanding of glucose and lipid metabolism.
In this review, we will discuss our current understanding of how
bile acids and the S1PR2 regulate hepatic lipid metabolism.2. Enterohepatic circulation of bile acids
Bile acids are synthesized from cholesterol in the hepatocytes and are
actively transported into the bile duct system using ATP-binding
cassette (ABC) transporter after conjugation with glycine or taurine.
Hepatocytes secrete bile acids via bile salt export proteins (BSEP,
ABCB11) along with phosphatidylcholine by ABCB4 and cholesterol
by ABCG5/ABCG89,10. As detergent molecules, bile acids keep
cholesterol in solution within the gallbladder by forming micelles with
cholesterol and phospholipids. The ratio of conjugated bile acids,
cholesterol and phospholipids is highly regulated and excess cholesterol
has been linked to an increased risk for cholesterol gallstone
formation11. Bile is stored in the gallbladder and excreted into the
duodenum in response to eating to activate pancreatic lipases and
solubilize lipids to promote dietary fat absorption. Approximately 95%
of bile acids are reabsorbed through the ileum by ileal sodium-
dependent bile acid transporter (IBAT, SLC10A2)12,13. Bile acids
reabsorbed from the intestines travel through the portal blood and
return to the liver via the sodium taurocholate cotransporting polypep-
tide (NTCP, SLC10A1)14. A small portion of primary bile acids are
converted into secondary bile acids by anaerobic gut bacteria, which
can be either passively absorbed from the large intestine or secreted inthe feces. During enterohepatic circulation, bile acids lost through fecal
excretion must be replenished by de novo bile acid synthesis.3. Bile acid synthesis
Bile acids are direct end-products of cholesterol catabolism. In
humans, two primary bile acids, CA (3α, 7α, 12α-trihydroxy-
cholanoic acid or cholic acid) and CDCA (3α, 7α-dihydroxy-
cholanoic acid or chenodeoxycholic acid), are formed in the liver
through two synthetic pathways, the neutral pathway and the
acidic pathway (Fig. 1). The neutral pathway, also called the
classic pathway, is the major pathway of generating bile acids for
humans under physiological conditions and produces both CA and
CDCA. The initiation of bile acid synthesis involves the enzyme
cholesterol 7α-hydroxylase (CYP7A1) to catalyze the 7α-
hydroxylation of cholesterol. In this rate-limiting step, CYP7A1
gene expression is tightly regulated at the transcriptional level and
by a negative feedback mechanism involving bile acids, glucagon,
tumor necrosis factor α (TNFα) and ﬁbroblast growth factor 15/19
(FGF15/19). In ileocytes, bile acids stimulate the production of
FGF15/19 which can bind to the ﬁbroblast growth factor receptor
4 (FGFR4)/β-Klotho complex on the cell membrane of hepato-
cytes and regulate bile acids and carbohydrate metabolism
via activating several signaling cascades including JNK1/2 and
ERK1/215–17. Activation of the JNK1/2 pathway has been shown
to repress Cyp7a1 gene expression in hepatocytes18. Fgfr4 and
β-Klotho null mice have been shown to contain increased Cyp7a1
mRNA levels and bile acid levels. These results demonstrate the
critical role FGF15/19, an FXR target gene, plays in the regulation
of CYP7A1 and bile acid synthesis. In addition, FXRα can induce
the expression of an atypical orphan nuclear receptor, small
heterodimer partner (SHP). SHP has no DNA-binding domain
and functions as a common transcriptional repressor of nuclear
receptors. SHP can form a heterodimer with several transcription
factors, including hepatocyte nuclear factor 4α (HNF-4α) and
liver-related homolog-1 (LRH-1), to inhibit their transactivation
activities, which results in inhibiting Cyp7a1 and sterol 12α-
hydroxylase (Cyp8b1) transcription19,20.
The acidic pathway is initiated by sterol 27-hydroxylase
(CYP27A1) in the mitochondrial inner membrane and has
been shown to be more active in cirrhosis and various liver
diseases21,22. Since cholesterol concentration is very low in the
inner mitochondrial membrane, the rate limiting step in acidic
pathway may be the transport of cholesterol into the mitochon-
drion. The acidic pathway generates mostly CDCA. In addition to
the liver, CYP27A1 is ubiquitously expressed in most tissues
including the macrophages. CYP27A1 can catalyze cholesterol to
form oxysterols by introducing a hydroxyl group to the carbon
at either the 27 or 25 position in cholesterol23–25. The products,
27-hydroxycholesterol and 25-hydroxycholesterol, are known to
be regulatory oxysterols that are important in maintaining choles-
terol and fat levels in the liver26.
Figure 1 Bile acid synthesis and metabolism. Two major pathways
are involved in bile acid synthesis. The neutral (or classic) pathway is
controlled by CYP7A1 in the endoplasmic reticulum. The acidic (or
alternative) pathway is initiated by sterol CYP27A1 in mitochondria.
CYP8B1 is required to synthesize CA. Oxysterol 7α-hydroxylase
(CYP7B1) is involved in the formation of CDCA in the acidic
pathway. The neutral pathway is also able to form CDCA by
CYP27A1. Primary bile acids are metabolized by gut bacteria to form
the secondary bile acids, DCA and LCA.
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deoxycholic acid (DCA) and lithocholic acid (LCA) respectively
by a small population of intestinal anaerobic bacteria.4. Sphingosine-1-phosphate and sphingosine-1-phosphate
receptors
Sphingosine-1-phosphate (S1P) is a simple, but potent bioactive
sphingolipid. It is involved in a variety of cellular processes,
including cell proliferation, differentiation, motility, angiogenesis,
inﬂammation and malignant transformation27. S1P is synthesized
by sphingosine kinase 1 (SphK1) or sphingosine kinase 2
(SphK2), which transfer the phosphate from ATP to the
1-hydroxyl group of sphingosine. SphK1 and SphK2 reside in
different subcellular compartments and regulate the production of
S1P. SphK1 is located in the cytoplasm, and upon an external
signal, it translocates to the plasma membrane to convert sphin-
gosine to S1P. Intracellular S1P can act as a signaling molecule,
but its target has not been well-characterized. S1P can be
converted to sphingosine by cytosolic S1P phosphatases or
degraded by S1P lyase (SPL) to ethanolamine phosphate and
hexadecanal. In order to activate the cell surface GPCRs, S1P must
be transported to the cell's exterior, but S1P is a small polarphospholipid and cannot easily pass the membrane lipid bilayer
without transporters. ABC transporters, including ABCA1 and
ABCC1, have been identiﬁed as active transporters of S1P28,29. In
addition, spinster homologue 2 (Spns2), a member of the major
facilitator superfamily, has been shown to mediate S1P secre-
tion30,31. Extracellular S1P exerts its function via activating ﬁve
different G protein coupled receptors (S1PR1–5) on the cell
membrane to induce various cellular responses32–34 (Fig. 2). In
the nucleus, pERK1/2 phosphorylates and activates SphK2 to
synthesize S1P. Nuclear S1P has been identiﬁed as a potent
histone deacetylase 1 and 2 inhibitor34.
S1PRs are differentially expressed in various tissues, and the
individual S1PR expression level varies under different physiolo-
gical and pathological conditions35. Each S1PR is coupled to
speciﬁc G proteins, which mediate unique functions. S1PR1 is
ubiquitously expressed and plays a key role in angiogenesis,
vascular maturation and immune cell trafﬁcking36,37. Deletion of
S1PR1 affects maturation and is embryonically lethal38. S1PR1
has been reported only to be linked with Gαi39. S1PR2 is highly
expressed in vascular smooth muscle cells, heart, liver, kidney,
spleen, lung and brain40,41. Unlike S1PR1, mice deﬁcient in
S1PR2 exhibit no phenotypic defects, but develop spontaneous
and sporadic seizures42. S1pr2 / mouse studies have also shown
S1PR2 to be responsible for proper development of the auditory
and vestibular systems43. In addition, S1PR2 is coupled to
different G proteins. Each of these G proteins activates different
pathways involved in various biological processes. S1PR2 has
been reported to be required for mast cell degranulation and
chemotaxis towards the site of inﬂammation44. S1PR3 is highly
expressed in the brain, heart, lung, spleen, kidney, liver, intestine
and skeletal muscle45. Similar to S1PR2, S1PR3 is also coupled to
different G proteins. S1PR3 plays an important role in pulmonary
epithelial and endothelial barriers46. S1PR4 is primarily expressed
in leukocytes and has been suggested to be a regulator of T cell
cytokine production47. S1PR5 expression is largely localized in the
white matter of the central nervous system with oligodendrocytes
having the highest expression. S1pr5 knockout mice did not
exhibit any changes in myelination48. The functional role of
S1PR5 is unclear. However, recent studies have suggested a role
in natural killer cells (NK) mobilization in the immune system41,49.5. Bile acids, S1PR2 and lipid metabolism
The role of bile acids regulating lipid metabolism in humans has
been well established. Cholesterol gallstone patients treated with
CDCA experience a decrease in hepatic very-low-density lipopro-
tein (VLDL) production and plasma triglyceride levels. Patients
with hypercholesterolemia received bile acid binding resins, which
increased serum levels of VLDL-triglycerides and high density
lipoprotein (HDL)-cholesterol while reducing low-density lipopro-
tein (LDL)-cholesterol levels50–52. It has been proposed that bile
acids regulate hepatic lipid homeostasis through the coordinate
regulation of Fxr, Shp, Lxr and Srebp1c genes53. In this model,
FXR-induced activation of SHP interacts with LXR to suppress
the transcriptional activity of SREBP-1c, a transcription factor
known to induce genes involved in fatty acid, triglyceride and
VLDL biosynthesis53–55. In addition, FXR induces the expression
of genes that regulate lipoprotein and triglyceride metabolism,
including ApoA-V, ApoC-II, ApoC-III, ApoE, PPARα and
syndecan-156–58. Fxr / mice have been shown to accumulate
hepatic lipids, cholesterol and triglycerides, whereas wild type
Figure 2 Sphingosine-1-phosphate-mediated signaling pathways. Intracellular S1P is synthesized from sphingosine by SphK1. S1P can be
converted back to sphingosine by S1P phosphatases (SPPs) or degraded to ethanolamine-1-phosphate and hexadecenal by SPL. Intracellular S1P
can directly activate various cellular signaling pathways or be exported out of cells by speciﬁc transporters in the cell membrane. Extracellular S1P
exerts its biological functions through activation of ﬁve G-protein coupled receptors, which are coupled to different G proteins and activate
different cellular responses.
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treatment with bile acids or FXR agonists59. The FXR inducible
gene, FGF19, has been shown to repress lipogenesis and increase
metabolism. Fgf19 transgenic mice exhibited resistance to diet-
induced obesity and insulin resistance60–64. Interestingly, over-
expressing Cyp7a1 in mice prevents fat-induced obesity and
insulin resistance65.
S1PR2 is highly expressed in the liver and plays a unique and
critical role in the pathophysiology of the liver. The role of S1PR2
in bile acid-mediated hepatic lipid metabolism was identiﬁed in
recent studies. In primary rodent hepatocytes, conjugated bile
acids activate S1PR2, which further activates the downstream
ERK1/2 and AKT signaling pathways. Bile acid-mediated activa-
tion of ERK1/2 and AKT signaling pathway plays an important
role in the regulation of hepatic glucose and lipid metabo-
lism33,66,67. In primary rat hepatocytes, insulin and bile acids both
activated glycogen synthase activity to a similar extent. Infusion of
taurocholate (TCA) into the chronic bile ﬁstula rat rapidly
activated the AKT and ERK1/2 signaling pathway and glycogen
synthase activity68. In addition, TCA induced a rapid down-
regulation of the gluconeogenic genes, PEP carboxykinase (Pepck)
and glucose-6-phophatase (G-6Pase) and a marked up-regulation
of Shp mRNA in the livers67. These results suggest that TCA has
insulin-like activity to regulate hepatic glucose metabolism both
in vitro and in vivo.
A recent study reported S1pr2 null mice rapidly develop overt
fatty livers on a high fat diet compared to wild-type mice,
suggesting that S1PR2 is an important regulator of hepatic lipid
metabolism69. Infusion of taurocholate into the chronic bile ﬁstula
rat or overexpression of the gene encoding S1PR2 in mouse
hepatocytes signiﬁcantly up-regulated hepatic SphK2, but not
SphK1. Interestingly, key genes encoding nuclear receptors/
enzymes involved in nutrient metabolism were signiﬁcantly
down-regulated in livers of S1pr2 / and Sphk2 / mice. In
contrast, overexpression of the gene encoding S1PR2 in primary
mouse hepatocytes increased mRNA levels of key genes involved
in nutrient metabolism. Previous studies have identiﬁed nuclear
S1P as an endogenous inhibitor of HDAC1/234. In the primaryhepatocytes of S1pr2 / and Sphk2 / mice, nuclear S1P levels
and the acetylation of H3K9, H4K5 and H2BK12 were signiﬁ-
cantly decreased. Both S1pr2 / and Sphk2 / mice rapidly
developed fatty livers on a high fat diet suggesting the importance
of conjugated bile acids, S1PR2 and SphK2 in regulating hepatic
lipid metabolism. Our previous studies in rodent hepatocytes and
human hepatocytes also reported that bile acid-induced ERK1/2
activation can be blocked not only by pertussis toxin (PTX), but
also by the epidermal growth factor receptor (EGFR; ErbB-1)
antagonist (AG1478) and the proto-oncogene tyrosine-protein
kinase (SRC) inhibitor PP270. As illustrated in Fig. 3, inhibition
of S1PR2 activation either by chemical antagonist (JTE-013) or
PTX will block ERK1/2 activation in hepatocytes, suggesting that
S1PR2-mediated signaling is the upstream of EGFR-mediated
signaling.
Inﬂammation is believed to be an important factor in the
development of type 2 diabetes and fatty liver disease. A Western
diet is correlated with low grade chronic inﬂammation and insulin
resistance. Inhibition of the insulin signaling pathway may
decrease the ability of bile acids to activate FXRα and induce
SHP and other FXR target genes, leading to an increased risk of
fatty liver and non-alcoholic fatty liver disease (NAFLD). It has
been reported that S1P inhibits macrophage migration to the
inﬂammation site via S1PR2 activation71. Hepatocyte proliferation
and matrix remodeling occur during liver injury, and S1PR2 has
been suggested to play a role in promoting the wound healing
response72.6. Conclusions and future directions
Bile acids mediate complex biological activities. Current data
supports the extensive interplay between bile acid-mediated
signaling and insulin signaling in the regulation of lipid and
nutrient metabolism in the liver. Bile acids not only activate
nuclear receptors, but also activate GPCRs. The emerging roles of
bile acids and S1PR2 in hepatic lipid metabolism have paved the
way for the future direction of bile acid signaling research.
Figure 3 Conjugated bile acids regulate sterol and lipid metabolism via activating S1PR2. In hepatocytes, CBA activates the S1PR2 on the cell
membrane, which induces the activation of ERK1/2 through activation of Gi protein. Activation of Gi will further induce activation of SRC, which
can activate the matrix metalloproteinase (MMP) and EGFR. EGFR-induced ERK1/2 activation can directly activate gene transcription in the
nucleus or further induce the activation of nuclear SPHK2 and the increase of nuclear S1P levels. Nuclear S1P is a strong inhibitor of nuclear
HDAC1/2. Inhibition of HDAC will increase the acetylation and transcription of a lot of genes involved in nutrient and lipid metabolism such as
CYP7A1, SREBP1c and ApoB-100.
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activation by bile acids and S1PR2 has on hepatic lipid metabo-
lism. Future studies aimed at elucidating the downstream target
genes of ERK1/2 and the mechanisms by which these genes are
activated are important. Since the identiﬁcation of GPCR, a lot of
drugs have been developed to treat various diseases. GPCRs are
the most successful category of drug targets to date73. Under-
standing the molecular basis of bile acids and S1PR2 in signaling
pathways may provide an avenue for drug targets and therapeutic
discoveries in various hepatic lipid disorders.Acknowledgements
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